Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Phase 3 ◽

Abstract not available.

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.102 ◽

2020 ◽

Vol 4 (6) ◽

pp. s102

Author(s):

Stephan Weidinger ◽

Jonathan Silverberg ◽

Darryl Toth ◽

Thomas Bieber ◽

Andrew Alexis ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Abstract not available.

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis

JAAD International ◽

10.1016/j.jdin.2021.11.001 ◽

2022 ◽

Vol 6 ◽

pp. 27-36

Author(s):

Norito Katoh ◽

Yukihiro Ohya ◽

Hiroyuki Murota ◽

Masanori Ikeda ◽

Xiaofei Hu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Blind Study ◽

Double Blind Study ◽

Phase 3 ◽

Double Blind ◽

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

10.1016/j.jaad.2020.06.198 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB28

Author(s):

Peter Lio ◽

Audrey Nosbaum ◽

Tracy Cardillo ◽

Amy DeLozier ◽

Margaret Gamalo ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Inadequate Response ◽

Phase 3 ◽

Skin Symptoms ◽

Patient Reported

Safety of Specifically Targeting Interleukin 13 with Tralokinumab in Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.11 ◽

2021 ◽

Vol 5 (1) ◽

pp. s11

Author(s):

Eric Simpson ◽

Joseph Merola ◽

Jonathan Silverberg ◽

Rebecca Zachariae ◽

Rebecca Olsen ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Adult Patients ◽

Phase 2 ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 13

Abstract not available.

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up)

SSRN Electronic Journal ◽

10.2139/ssrn.3748383 ◽

2020 ◽

Author(s):

Kristian Reich ◽

Henrique D. Teixeira ◽

Marjolein de Bruin-Weller ◽

Thomas Bieber ◽

Weily Soong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Controlled Study ◽

Phase 3 ◽

Pivotal Phase ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Topical Corticosteroids ◽

Adolescents And Adults

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(17)31191-1 ◽

2017 ◽

Vol 389 (10086) ◽

pp. 2287-2303 ◽

Cited By ~ 364

Author(s):

Andrew Blauvelt ◽

Marjolein de Bruin-Weller ◽

Melinda Gooderham ◽

Jennifer C Cather ◽

Jamie Weisman ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded ◽

Term Management

28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

10.1016/j.jaad.2021.06.697 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB171

Author(s):

Andrew Blauvelt ◽

Michael R. Ardern-Jones ◽

Thomas Bieber ◽

Chih-ho Hong ◽

Chia-Yu Chu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

26053 Improvement in sleep is associated with improved quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a phase 3 trial of baricitinib therapy

10.1016/j.jaad.2021.06.080 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB14

Author(s):

Peter Lio ◽

George Han ◽

Edward Lain ◽

Catherine Maari ◽

Susan Ball ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3

26292 Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study

10.1016/j.jaad.2021.06.402 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB96

Author(s):

David Rosmarin ◽

Scott Fretzin ◽

Lindsay Strowd ◽

Marta Casillas ◽

Amy DeLozier ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Rapid Improvement ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Skin Pain

A Study to Test Safety and Tolerability of a Study Drug Called MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Patients With Moderate to Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct03864627 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Study Drug ◽

Adult Patients ◽